IN THE CLAIMS:

Claim 1-65. (Cancelled).

Claim 66. (Currently amended) A method for treating ~~**or preventing**~~ an anemic condition in a subject, the method comprising administering to the subject a therapeutic amount of a recombinant erythropoietin produced in baby hamster kidney cells, the recombinant erythropoietin **consisting essentially of Epoetin Omega** ~~**being other than Epoetin Alfa or Beta**~~, wherein the amount of recombinant erythropoietin administered is selected to provide a therapeutic benefit within a treatment period, and wherein ~~**prior treatment of**~~ the subject ~~**with a therapeutic amount of**~~ **is non responsive when treated with a therapeutic amount Epoetin Alfa or Beta** ~~**did not provide a therapeutic benefit within a treatment period**~~.

Claim 67. (Withdrawn) The method of claim 66 wherein the erythropoietin is Epoetin Omega.

Claim 68. (Previously presented) The method of claim 66 wherein the anemic condition is associated with an anemia associated with a renal condition.

Claim 69. (Withdrawn) The method of claim 66 wherein the treatment is for preventing an anemic condition associated with an operative procedure.

Claim 70. (Withdrawn) The method of claim 66 wherein the recombinant erythropoietin is administered in a preoperative step.

Claim 71. (Withdrawn) The method of claim 66 wherein the operative procedure is bone marrow transplantation.

Claim 72. (Withdrawn) The method of claim 66 wherein the anemic condition is associated with a heart condition.

Claim 73. (Withdrawn) The method of claim 66 wherein the anemic condition is associated with liver dysfunction.

Claim 74. (Withdrawn) The method of claim 66 wherein the anemic condition is associated with hepatitis.

Claim 75. (Withdrawn) The method of claim 66 wherein the anemic condition is associated with cancer.

Claim 76. (Original) The method of claim 66 wherein the therapeutic benefit is selected from the group consisting of increased RBC, increased HCT, increased hemoglobin and increased vigor.

Claim 77. (Original) The method of claim 66 wherein the recombinant erythropoietin is administered at a dose of about 5 to about 150 IU/Kg, one to three times per week.

Claim 78. (Original) The method of claim 66 wherein the recombinant erythropoietin is administered at a dose of about 10 to about 100 IU/Kg, one to two times per week.

Claim 79. (Original) The method of claim 66 wherein the recombinant erythropoietin is administered at a dose of about 10 to about 75 IU/Kg, one to two times per week.

Claim 80. (Original) The method of claim 66 wherein the recombinant erythropoietin is administered at a dose of about 25 to about 60 IU/Kg, two times per week.

Claim 81. (Original) The method of claim 66 wherein the recombinant erythropoietin is administered at a dose of about 25 to about 35 IU/Kg, two times per week.

Claim 82. (Original) The method of claim 66 wherein the recombinant erythropoietin is administered at a dose of about 75 to about 150 IU/Kg, once per week.

Claim 83. (Original) The method of claim 66 wherein the recombinant erythropoietin is administered at a dose of about 75 to about 100 IU/Kg, once per week.

Claim 84. (Original) The method of claim 66 wherein the treatment period includes a titration period and the recombinant erythropoietin is administered at an initial dose of about 50 to about 100 IU/Kg per week during the titration period and is adjusted by about 5 to about 25 IU/Kg/week to obtain a hemoglobin count of about 10 to about 12 g/dl.

Claim 85. (Original) The method of claim 66 wherein the treatment period further includes a maintenance period, and the recombinant erythropoietin is administered at a dose of about 40-60 IU/Kg per week during the maintenance period.

Claim 86. (Withdrawn) The method of claim 66 wherein the anemic condition is associated with a cancer therapy.

Claim 87. (Withdrawn) The method of claim 86 wherein the cancer therapy is a chemotherapy.

Claim 88. (Withdrawn) The method of claim 97 wherein the chemotherapy is a cisplatinum therapy.

Claim 89. (Withdrawn) The method of claim 86 wherein the recombinant erythropoietin is administered before, during, or after the cancer therapy.

Claims 90-116. (Cancelled).

Claim 117. (Currently amended) A method for treating ~~**or preventing**~~ an anemic condition in a subject, the method comprising administering to the subject a therapeutic amount of a recombinant erythropoietin produced in baby hamster kidney cells, the recombinant erythropoietin **consisting essentially of Epoetin Omega** ~~**being other than Epoetin Alfa or Beta**~~, wherein the amount of recombinant erythropoietin administered is selected to provide a therapeutic benefit within a treatment period, and wherein ~~**prior treatment of**~~ the subject ~~**with a therapeutic amount of**~~ **is adversely effected when treated with a therapeutic amount Epoetin Alfa or Beta** ~~**did not provide a therapeutic benefit within a treatment period**~~.

Claim 118. (Previously presented) The method of claim 117 wherein the adverse effect is selected from the group consisting of hypertension, headache, arthralgia, nausea, edema, fatigue, diarrhea, vomiting, chest pain, skin rash, dizziness, thrombosis and increased blood platelets.

Claim 119. (Previously presented) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 5 to about 150 IU/Kg, one to three times per week.

Claim 120. (Previously presented) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 10 to about 100 IU/Kg, one to two times per week.

Claim 121. (Previously presented) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 10 to about 75 IU/Kg, one to two times per week.

Claim 122. (Previously presented) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 25 to about 60 IU/Kg, two times per week.

Claim 123. (Previously presented) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 25 to about 35 IU/Kg, two times per week.

Claim 124. (Previously presented) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 75 to about 150 IU/Kg, once per week.

Claim 125. (Previously presented) The method of claim 117 wherein the recombinant erythropoietin is administered at a dose of about 75 to about 100 IU/Kg, once per week.

Claim 126. (Previously presented) The method of claim 117 wherein the treatment period includes a titration period and the recombinant erythropoietin is administered at an initial dose of about 50 to about 100 IU/Kg per week during the titration period and is adjusted by about 5 to about 25 IU/Kg/week to obtain a hemoglobin count of about 10 to about 12 g/dl.

Claim 127. (Previously presented) The method of claim 117 wherein the treatment period further includes a maintenance period, and the recombinant erythropoietin is administered at a dose of about 40-60 IU/Kg per week during the maintenance period.

Claim 128. (Withdrawn) The method of claim 117 wherein the erythropoietin is Epoetin Omega.

Claim 129. (Previously presented) The method of claim 117 wherein the anemic condition is an anemia associated with a renal condition.

Claim 130. (Previously presented) The method of claim 117 wherein the therapeutic benefit is selected from the group consisting of increased RBC, increased HCT, increased hemoglobin, and increased vigor.